)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jyong Biotech
Jyong Biotech (MENS) investor relations material
Jyong Biotech Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary15 May, 2026
Executive summary
Focused on developing and commercializing plant-derived drugs for urinary system diseases, with three main candidates: Botreso® (BPH/LUTS), PCP (prostate cancer prevention), and IC (interstitial cystitis).
Completed IPO in June 2025, raising $17.8 million net proceeds.
No product revenue generated; operations funded by equity, loans, and related party transactions.
Financial highlights
Net losses: $4.7M (2025), $3.0M (2024), $4.4M (2023); accumulated deficit $37.8M as of Dec 31, 2025.
R&D expenses: $813K (2025), $927K (2024), $1.1M (2023); G&A expenses: $1.7M (2025), $1.1M (2024), $1.7M (2023).
Cash used in operations: $3.0M (2025), $3.6M (2024), $2.6M (2023); cash and equivalents: $1.2M at end of 2025.
No revenue recognized in 2023–2025.
Outlook and guidance
Significant additional funding required to continue operations and clinical development; substantial doubt about ability to continue as a going concern.
Plans to pursue further public offerings, credit facilities, or strategic collaborations.
Expenses expected to increase as clinical programs advance and public company costs rise.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jyong Biotech
- Biotech with no revenue seeks Nasdaq IPO to fund trials, facing high financial and legal risks.MENS
Registration Filing - Pre-revenue biotech targeting urinary diseases seeks Nasdaq IPO amid high financial and regulatory risk.MENSRegistration Filing
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing
- Biotech seeks Nasdaq IPO to fund clinical trials amid high financial and regulatory risk.MENSRegistration Filing
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high financial and legal risks.MENSRegistration Filing
- Biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and financial risk.MENSRegistration Filing
- Biotech seeks $17.8M IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing
- Biotech with no revenue, large deficits, and legal risks seeks IPO to fund clinical trials.MENSRegistration Filing
Next Jyong Biotech earnings date
Q4 202623 Apr, 2027
Jyong Biotech
Next Jyong Biotech earnings date
Q4 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)